(Q43813017)

27 November 2017

title

Exploring causes for declining prostate cancer mortality rates in the United States (English)

1 reference

27 November 2017

main subject

United States of America

0 references

author name string

Janet L Colli

series ordinal

1

1 reference

27 November 2017

Christopher L Amling

series ordinal

2

1 reference

27 November 2017

publication date

14 January 2008

1 reference

27 November 2017

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

6

1 reference

27 November 2017

page(s)

627-633

1 reference

Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

International trends in prostate-cancer mortality in the "PSA ERA".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

The role of cholesterol in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

National trends in statin use by coronary heart disease risk category

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Hypothesis: the antitumor activities of statins may be mediated by IL-18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Statins and prostate cancer risk: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Statin drugs and risk of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Statin use and the risk of breast and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

State trends in health risk factors and receipt of clinical preventive services among US adults during the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

The validity of male patients' self-reports regarding prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

The accuracy of primary care patients' self-reports of prostate-specific antigen testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.016

10.1016/J.UROLONC.2007.05.016

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference